- Home
- AUPH vs MLKN Comparison
AUPH vs MLKN Comparison
Compare AUPH & MLKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- MLKN
- Stock Information
- Founded
- AUPH 1993
- MLKN 1905
- Country
- AUPH Canada
- MLKN United States
- Employees
- AUPH N/A
- MLKN N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- MLKN Office Equipment/Supplies/Services
- Sector
- AUPH Health Care
- MLKN Consumer Discretionary
- Exchange
- AUPH Nasdaq
- MLKN Nasdaq
- Market Cap
- AUPH 1.4B
- MLKN 1.2B
- IPO Year
- AUPH 1999
- MLKN N/A
- Fundamental
- Price
- AUPH $12.22
- MLKN $21.11
- Analyst Decision
- AUPH Strong Buy
- MLKN
- Analyst Count
- AUPH 4
- MLKN 0
- Target Price
- AUPH $12.25
- MLKN N/A
- AVG Volume (30 Days)
- AUPH 2.8M
- MLKN 372.4K
- Earning Date
- AUPH 07-31-2025
- MLKN 09-18-2025
- Dividend Yield
- AUPH N/A
- MLKN 3.53%
- EPS Growth
- AUPH N/A
- MLKN N/A
- EPS
- AUPH 0.42
- MLKN N/A
- Revenue
- AUPH $260,111,000.00
- MLKN $3,669,900,000.00
- Revenue This Year
- AUPH $12.15
- MLKN $4.74
- Revenue Next Year
- AUPH $18.34
- MLKN $3.64
- P/E Ratio
- AUPH $29.06
- MLKN N/A
- Revenue Growth
- AUPH 25.59
- MLKN 1.14
- 52 Week Low
- AUPH $6.23
- MLKN $15.25
- 52 Week High
- AUPH $12.53
- MLKN $30.56
- Technical
- Relative Strength Index (RSI)
- AUPH 78.39
- MLKN 60.63
- Support Level
- AUPH $11.18
- MLKN $19.62
- Resistance Level
- AUPH $11.69
- MLKN $21.84
- Average True Range (ATR)
- AUPH 0.60
- MLKN 0.71
- MACD
- AUPH 0.12
- MLKN 0.15
- Stochastic Oscillator
- AUPH 91.61
- MLKN 80.22
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About MLKN MillerKnoll Inc.
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.